CellFiber and Locus Cell Establish Commercial-Scale Manufacturing for Human Umbilical Cord-Derived Mesenchymal Stem Cells Using Advanced 3D Culture Technology

PR TIMES Japan

Overview

Japan’s CellFiber and its Taiwanese partner Locus Cell have successfully established a commercial-scale manufacturing process for human umbilical cord-derived mesenchymal stem cells (UC-MSC) utilizing the innovative CellFiber® technology. This advanced 3D encapsulation method protects cells within alginate gel tubes, enhancing cell function maintenance and ensuring consistent quality superior to conventional 2D cultures. Locus Cell has integrated this GMP-compliant system into its new automated smart factory in Hsinchu, Taiwan, enabling large-scale production of cell-based therapeutics and marking a significant leap toward wider cellular medicine accessibility.

In Depth

Background and Challenges in Cell-Based Therapeutic Manufacturing

Regenerative medicine and cell-based therapeutics hold immense promise for treating numerous intractable diseases. However, their widespread commercialization is critically dependent on establishing large-scale, high-quality cell manufacturing processes. Mesenchymal Stem Cells (MSCs), for example, are highly susceptible to functional degradation and quality variability during traditional two-dimensional (2D) culture. Conventional methods struggle with scalability, cost-effectiveness, reproducibility, and consistency, posing significant barriers to bringing these advanced therapies to patients.

Japan’s CellFiber Inc. has been at the forefront of addressing these challenges, developing its proprietary “CellFiber® technology,” and collaborating with Taiwan’s Locus Cell Co., Ltd. to translate this innovation into practical, commercial-scale solutions.

CellFiber® Technology and Commercial-Scale UC-MSC Production

CellFiber® technology is a next-generation three-dimensional (3D) cell culture platform that encapsulates cells within tube-like structures made of alginate gel. Key features of this innovative technology include:

• Enhanced Cell Protection and Viability: The alginate gel physically protects cells, mitigating stress during culture. This allows cells, such as UC-MSCs, to maintain their inherent functions (e.g., proliferation, differentiation potential, immunomodulatory properties) for extended periods with high viability, critical for therapeutic efficacy.
• High-Density Culture and Scalability: The tubular structure facilitates high-density cell culture, enabling easier and more efficient scale-up into bioreactors for large-scale production. This is a crucial advantage for the commercialization of cell-based pharmaceuticals.
• Consistent Quality: By providing a uniform culture environment, the technology helps reduce batch-to-batch variability, contributing to the production of consistently high-quality cell products—a paramount concern for regulatory approval and clinical success.

Locus Cell has successfully applied CellFiber® technology to the manufacturing process of human umbilical cord-derived mesenchymal stem cells (UC-MSC), establishing a large-scale, commercial-grade production process. This achievement was realized through the integration of the CellFiber® system into Locus Cell’s newly inaugurated automated smart factory in Hsinchu, Taiwan, which is designed for Good Manufacturing Practice (GMP)-compliant cell-based therapeutic production.

Industry Impact and Future Outlook

The establishment of this commercial-scale manufacturing process by Locus Cell represents a significant advancement for the broader cell-based therapeutic industry. UC-MSCs, in particular, are garnering extensive interest due to their high regenerative capacity and immunomodulatory properties, making them promising candidates for various therapeutic applications. The efficient and high-quality production of UC-MSCs using CellFiber® technology is expected to have several impacts:

• Accelerated Therapy Accessibility: By reducing manufacturing costs and improving supply stability, cell-based therapies utilizing UC-MSCs could become more accessible and affordable for a wider patient population.
• Enhanced Quality Control: The ability to consistently supply high-quality cells increases the success rate of clinical trials and facilitates regulatory approvals, a critical hurdle for novel therapies.
• Strengthened International Competitiveness: This collaboration between Japanese and Taiwanese companies in establishing cutting-edge cell manufacturing technology reinforces the international competitiveness of the regenerative medicine industry in the Asia-Pacific region.

Looking ahead, this technology is anticipated to be applicable to various other cell types, contributing to the overall development of the cell-based pharmaceutical industry. It also serves as a testament to Japan’s technological leadership in the regenerative medicine sector on a global scale, pushing the boundaries of what is possible in advanced biomanufacturing.